Ratings Innate Pharma

Equities

IPH

FR0010331421

Market Closed - Euronext Paris Other stock markets 11:35:03 2024-05-21 am EDT			Pre-market 02:00:06 am
2.555 ^EUR	-2.85%		2.555	0.00%

May. 14	Transcript : Innate Pharma S.A., Q1 2024 Earnings Call, May 14, 2024
Apr. 15	Sanofi: progress in hematology trial	CF

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company has insufficient levels of profitability.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
INNATE PHARMA	-2.48%	224M	C-
MODERNA, INC.	+44.48%	55.07B	B-
LONZA GROUP AG	+43.57%	40.22B	A
IQVIA HOLDINGS INC.	-0.86%	41.79B	B
CELLTRION, INC.	-7.59%	28.17B	C
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B	B
BIO-TECHNE CORPORATION	+7.15%	13.03B	B+
MEDPACE HOLDINGS, INC.	+29.40%	12.26B	C+
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes